Ajinomoto Co., Inc. utilized data from CGT Catapult’s Industrialization group work to advance industrializing of cell therapies, highlighting the global reach of the Catapult initiative.
The Cell and Gene Therapy Catapult (CGT Catapult; London, UK) has announced it has licensed data from its pluripotent stem cell development program ‘Cell Plasticity’ to Japanese food and amino acid company Ajinomoto Co., Inc. (Japan) further advancing CGT Catapult’s place as one of the global leaders in the development of solutions for the industrialization of cell therapies. Through utilizing process and analytical data from CGT Catapult’s program, Ajinomoto Co. was able to evaluate the adherent expansion of CGT Catapult’s human induced pluripotent stem cell (iPSC) line CGT-RCiB10 in different culture systems.
CGT Catapult is dedicated to supporting the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialization. As part of this, CGT Catapult has been working to develop scalable processing platforms of pluripotent stem cells and their derivatives, and therefore support the translation of research into commercially viable advanced therapy medicinal products. The continued focus from CGT on developing novel products, such as the pluripotent stem cell program, provides the organization with the opportunity to collaborate with academic and commercial partners across the world in some of the most innovative and promising areas of medical research.
“We are thrilled that our research continues to be sought after by organizations across the globe. The licensing of this data to Ajinomoto Co. highlights the benefit and skills we continue to bring to these organizations, and through them, how the Catapult is able to contribute to the advancement of technologies and medicines of the future,” said Keith Thompson, Chief Executive Officer, Cell and Gene Therapy Catapult.